Canaccord raised the firm’s price target on Verona Pharma (VRNA) to $44 from $37 and keeps a Buy rating on the shares. The firm said they reported Q3 results and noted Ohtuvayre initial sales beat expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma price target raised to $42 from $36 at H.C. Wainwright
- Verona Pharma Faces Financial Risks Amid Medicaid Rebate Program Compliance Challenges
- Verona Pharma Reports Strong Q3 Launch for COPD Drug
- Verona Pharma reports Q3 EPS (7c), consensus (50c)
- Verona Pharma price target raised to $64 from $50 at Wells Fargo